BPC-157 research: what animal studies show

Almost all BPC-157 studies are animal studies, mostly in rats, and the human evidence is still thin. A 2025 systematic review in orthopedic sports medicine found 36 eligible papers published between 1993 and 2024: 35 were preclinical and only one was a clinical study, a small retrospective case series. The first randomized, placebo-controlled human trials are only now being run. This page maps what has been studied, in which models, how strong the evidence is, and which human trials are registered or published as of October 2026.

Where BPC-157 comes from

A 2025 literature and patent review in Pharmaceuticals (Józwiak and colleagues) describes BPC-157 as a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1419.55 daltons. It traces back to work by Sikiric and colleagues, who first described it in 1993 as isolated from human gastric juice. For background on what peptides are, see what are peptides?

The evidence map: what animal studies cover

Two recent reviews give a good picture of the animal literature. The HSS Journal systematic review (Vasireddi and colleagues, July 2025) focused on musculoskeletal and sports medicine research. The Pharmaceuticals review covered other organ systems. Together they show a wide spread of models but very little replication outside rodents.

In the musculoskeletal subset of the HSS review, 11 of 13 studies used rats, one used rabbits and one involved humans. The authors concluded that the preclinical work "suggests" BPC-157 may support structural, biomechanical and functional recovery in tendon, ligament, muscle and fracture models, but they graded the evidence as level IV and V, the lowest tiers of the evidence pyramid.

Proposed mechanisms

The mechanisms in the literature are hypotheses drawn from animal and cell work, not established pathways in people. The Pharmaceuticals review lists:

• Nitric oxide signaling: BPC-157 counteracted the effects of the NOS inhibitor L-NAME in several rodent models.
• Angiogenesis: increased VEGFR-2 expression was reported in a hind-limb ischemia model.
• Antioxidant enzymes: raised levels of HO-1 and NQO-1 were reported.
• EGR-1: a growth-response gene suggested to be involved in wound and vessel effects.
• Neurotransmitters: changes in serotonin synthesis and dopamine signaling in rodent brain studies.

The same review notes a flip side. Growing new blood vessels is useful in wound models, but the authors flag pro-angiogenic activity as a possible concern where an undiagnosed cancer is present.

BPC-157 human trials: registered and published

People searching for "BPC 157 human trials" usually find claims of extensive human data. The verifiable record is short.

A few points about this list:

• The two published reports are not trials. Both lack control groups and rely on patient-reported outcomes. The HSS reviewers called the knee report retrospective with subjective outcomes; a drug-information review described it as highly limited by bias. Neither can show whether BPC-157 caused any change.
• The Phase 1 trial never reported. NCT02637284 tested an oral BPC-157 product called PCO-02 in healthy volunteers. The Pharmaceuticals review says submission of results was cancelled in 2016.
• Older ulcerative colitis studies exist only as abstracts. Conference abstracts from 2003 and 2005 describe a Phase 1 study and a Phase 2 ulcerative colitis study, but full data were never published in a form that can be checked.
• The hamstring trial is the one to watch. NCT07437547 is the first registered randomized, double-blind, placebo-controlled efficacy trial of BPC-157 we could verify. Its co-primary outcomes are time to return to unrestricted sport and MRI-measured injury volume at day 14. No results have been released.

Limits of the evidence

Both reviews end with similar cautions:

• Study designs and outcomes vary too much to pool the data in a meta-analysis.
• Most of the evidence comes from rodents, and few routes of administration have been tested.
• Animal adverse-event monitoring covered only up to six weeks in the musculoskeletal studies.
• There are no completed clinical efficacy studies, and human toxicity is unclear.
• Unregulated manufacturing raises contamination and identity concerns. If you work with research material, our guide to verifying a peptide COA explains what a certificate should show, and our page on synthetic peptide risks covers quality problems.

Regulatory and anti-doping status

BPC-157 is not approved by the FDA or any other major regulator. On 28 October 2026, HHS announced an enforcement-discretion policy that lets 503A pharmacies and physicians compound BPC-157 and five other peptides under set conditions while rulemaking continues. Legal commentators stress that this does not make compounded products FDA-approved. Our HHS peptide compounding policy explainer covers the details, and the peptide legal guide covers the wider US picture.

In sport, BPC-157 is named as an example in class S0 (non-approved substances) of the WADA Prohibited List, which means it is prohibited at all times. USADA's advisory on the 2027 list still lists it under S0. For a side-by-side with the other peptide most often discussed alongside it, see BPC-157 vs TB-500.

Frequently asked questions

Sources

1. Vasireddi et al., Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS Journal (31 July 2025)
2. Józwiak et al., Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review, Pharmaceuticals (30 January 2025)
3. InpharmD: summary of human BPC-157 studies
4. UroToday: Effect of BPC-157 on symptoms in patients with interstitial cystitis, a pilot study (October 2024)
5. Trial record: PCO-02 safety and pharmacokinetics trial (NCT02637284)
6. Trial record: BPC 157 for acute hamstring muscle strain repair (NCT07437547)
7. Trial record: Impact of BPC-157 on recovery following rotator cuff repair surgery (NCT07803250)
8. FDA Law Blog: HHS enforcement discretion for peptide compounding (28 October 2026)
9. USADA: Athlete advisory on the 2027 Prohibited List (6 October 2026)